ATNM – Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals, Inc. ATNM
$1.21Name : Actinium Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $37,747,040.00
EPSttm : -1.27
Actinium Pharmaceuticals, Inc.
$1.21
3.20%$0.04Float Short %
8.32
Margin Of Safety %
Put/Call OI Ratio
0.05
EPS Next Q Diff
EPS Last/This Y
0.04
EPS This/Next Y
0.24
Price
1.21
Target Price
5
Analyst Recom
1.4
Performance Q
-0.82
Relative Volume
0.54
Beta
-0.11
Ticker: ATNM
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-21 | ATNM | 1.54 | 0.07 | 0.01 | 1607 |
| 2025-03-24 | ATNM | 1.495 | 0.07 | 0.02 | 1693 |
| 2025-03-25 | ATNM | 1.585 | 0.07 | 0.28 | 1736 |
| 2025-03-26 | ATNM | 1.855 | 0.08 | 0.06 | 2203 |
| 2025-03-27 | ATNM | 1.91 | 0.06 | 0.04 | 2944 |
| 2025-03-28 | ATNM | 1.79 | 0.06 | 0.10 | 3085 |
| 2025-03-31 | ATNM | 1.61 | 0.05 | 0.11 | 3165 |
| 2025-04-01 | ATNM | 1.5 | 0.05 | 0.02 | 3168 |
| 2025-04-02 | ATNM | 1.545 | 0.05 | 0.00 | 3206 |
| 2025-04-03 | ATNM | 1.385 | 0.05 | 0.00 | 3212 |
| 2025-04-04 | ATNM | 1.29 | 0.05 | 0.43 | 3217 |
| 2025-04-07 | ATNM | 1.215 | 0.05 | 0.00 | 3212 |
| 2025-04-08 | ATNM | 1.21 | 0.05 | 0.00 | 3236 |
| 2025-04-09 | ATNM | 1.29 | 0.05 | 999.99 | 3252 |
| 2025-04-10 | ATNM | 1.165 | 0.05 | 6.50 | 3253 |
| 2025-04-11 | ATNM | 1.28 | 0.05 | 0.00 | 3253 |
| 2025-04-14 | ATNM | 1.305 | 0.05 | 0.00 | 3279 |
| 2025-04-15 | ATNM | 1.255 | 0.05 | 0.04 | 3288 |
| 2025-04-16 | ATNM | 1.25 | 0.05 | 0.00 | 3469 |
| 2025-04-17 | ATNM | 1.2 | 0.05 | 0.15 | 3499 |
| 2025-04-18 | ATNM | 1.21 | 0.05 | 0.15 | 3499 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-21 | ATNM | 1.54 | -18.2 | - | -1.43 |
| 2025-03-24 | ATNM | 1.49 | -18.2 | - | -1.43 |
| 2025-03-25 | ATNM | 1.58 | -18.2 | - | -1.43 |
| 2025-03-26 | ATNM | 1.87 | -18.2 | - | -1.43 |
| 2025-03-27 | ATNM | 1.92 | -18.2 | - | -1.43 |
| 2025-03-28 | ATNM | 1.81 | -18.2 | - | -1.43 |
| 2025-03-31 | ATNM | 1.61 | -18.2 | - | -1.43 |
| 2025-04-01 | ATNM | 1.49 | -18.2 | - | -1.43 |
| 2025-04-02 | ATNM | 1.52 | -18.2 | - | -1.43 |
| 2025-04-03 | ATNM | 1.38 | -18.2 | - | -1.43 |
| 2025-04-04 | ATNM | 1.29 | 6.5 | - | -1.15 |
| 2025-04-07 | ATNM | 1.22 | 6.5 | - | -1.23 |
| 2025-04-08 | ATNM | 1.21 | 6.5 | - | -1.23 |
| 2025-04-09 | ATNM | 1.26 | 6.5 | - | -1.23 |
| 2025-04-10 | ATNM | 1.16 | 6.5 | - | -1.23 |
| 2025-04-11 | ATNM | 1.27 | 6.5 | - | -1.23 |
| 2025-04-14 | ATNM | 1.32 | 6.5 | - | -1.23 |
| 2025-04-15 | ATNM | 1.26 | 6.5 | - | -1.23 |
| 2025-04-16 | ATNM | 1.25 | 6.5 | - | -1.23 |
| 2025-04-17 | ATNM | 1.21 | 6.5 | - | -1.23 |
| 2025-04-18 | ATNM | 1.21 | 6.5 | - | -1.23 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-21 | ATNM | 0.00 | -2.88 | 7.39 |
| 2025-03-24 | ATNM | 0.00 | -2.88 | 7.39 |
| 2025-03-25 | ATNM | 0.00 | -2.88 | 7.39 |
| 2025-03-26 | ATNM | 0.00 | -2.88 | 7.27 |
| 2025-03-27 | ATNM | 0.00 | -2.88 | 7.27 |
| 2025-03-28 | ATNM | 0.00 | -2.88 | 7.27 |
| 2025-03-31 | ATNM | 0.00 | -2.88 | 7.27 |
| 2025-04-01 | ATNM | 0.00 | -2.88 | 7.27 |
| 2025-04-02 | ATNM | 0.00 | -2.88 | 7.27 |
| 2025-04-03 | ATNM | 0.00 | -2.88 | 7.27 |
| 2025-04-04 | ATNM | 0.00 | -2.88 | 7.27 |
| 2025-04-07 | ATNM | 0.00 | -2.92 | 7.27 |
| 2025-04-08 | ATNM | 0.00 | -2.92 | 7.27 |
| 2025-04-09 | ATNM | 0.00 | -2.92 | 7.27 |
| 2025-04-10 | ATNM | 0.00 | -2.92 | 8.32 |
| 2025-04-11 | ATNM | 0.00 | -2.92 | 8.32 |
| 2025-04-14 | ATNM | 0.00 | -3.06 | 8.32 |
| 2025-04-15 | ATNM | 0.00 | -3.06 | 8.32 |
| 2025-04-16 | ATNM | 0.00 | -3.06 | 8.32 |
| 2025-04-17 | ATNM | 0.00 | -3.06 | 8.32 |
| 2025-04-18 | ATNM | 0.00 | -3.06 | 8.32 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.39
Avg. EPS Est. Next Quarter
-0.36
Insider Transactions
Institutional Transactions
-3.06
Beta
-0.11
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
8
Fair Value
Quality Score
5
Growth Score
21
Sentiment Score
21
Actual DrawDown %
93.8
Max Drawdown 5-Year %
-94.1
Target Price
5
P/E
Forward P/E
PEG
P/S
P/B
1.15
P/Free Cash Flow
EPS
-1.27
Average EPS Est. Cur. Y
-1.23
EPS Next Y. (Est.)
-0.99
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.54
Return on Equity vs Sector %
-136.7
Return on Equity vs Industry %
-123.3
EPS 1 7Days Diff
-0.5
EPS 1 30Days Diff
-0.53
EBIT Estimation
Actinium Pharmaceuticals, Inc. Sector: Healthcare
Industry: Biotechnology
Employees: 37
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
stock quote shares ATNM – Actinium Pharmaceuticals Inc Stock Price stock today
news today ATNM – Actinium Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ATNM – Actinium Pharmaceuticals Inc yahoo finance google finance
stock history ATNM – Actinium Pharmaceuticals Inc invest stock market
stock prices ATNM premarket after hours
ticker ATNM fair value insiders trading